Breaking News
May 27, 2018 - Study reveals striking disparities in health care access and quality across most nations
May 27, 2018 - The Yogi masters were right—meditation and breathing exercises can sharpen your mind
May 27, 2018 - SLU researcher aims to find solutions for diabetes patients at risk of hypoglycemia
May 27, 2018 - Scientists uncover the cause of insulin resistance in obesity
May 27, 2018 - $2.3 million NIH grant to support new project on oxytocin neurons and social behavior
May 27, 2018 - Less Driving Tied to Lower Cardiovascular Disease Risk
May 27, 2018 - Genetics Home Reference: LMNA-related congenital muscular dystrophy
May 27, 2018 - Long-term psychological study confirms time is the best medicine against homesickness
May 27, 2018 - Study explores if CPAP treatment can improve sexual QOL for sleep apnea patients
May 27, 2018 - Study investigates role played by brain in prosocial behavior
May 27, 2018 - New Guidelines Mean 1 in 3 Adults May Need Blood Pressure Meds
May 27, 2018 - Cerebrospinal Fluid (CSF) Analysis: MedlinePlus Lab Test Information
May 27, 2018 - Kids in tough neighborhoods head to ER more often
May 27, 2018 - Exercise alters brain’s dopamine system to help treat addiction, study finds
May 27, 2018 - Sepsis patients treated and released from ED for outpatient follow-up experience good outcomes
May 27, 2018 - Initiative cuts overuse of tests, treatments for bronchiolitis
May 27, 2018 - Study links ‘sleep spindles’ to memory reactivation
May 27, 2018 - Scientists develop new method to speed up genome evolution of baker’s yeast
May 27, 2018 - Sunscreen pills are fake says FDA
May 27, 2018 - Study finds increasing wealth gap between households of seniors and families with children
May 27, 2018 - Link between tuberculosis and Parkinson’s disease discovered
May 27, 2018 - Doctors call on health authorities for permission to provide stroke patients with life-saving treatment
May 26, 2018 - Couples who eat seafood-rich diet tend to get pregnant faster
May 26, 2018 - NIH summit presents recommendations to accelerate treatment development for Alzheimer’s disease
May 26, 2018 - Medication-related harm found to be common among older adults, but preventable
May 26, 2018 - Lunaphore and Vitro announce partnership to develop ISH protocols for RNA, DNA targets
May 26, 2018 - Cryoablation Efficacious for Cancer Pain, Review Finds
May 26, 2018 - Link between IBD and Parkinson’s might allow doctors to slow down condition
May 26, 2018 - Study finds fewer than 5% of low-income, urban mothers use prenatal vitamins before pregnancy
May 26, 2018 - California hospitals urge moms to favor breast milk over formula
May 26, 2018 - Most concussion patients do not receive follow-up care after hospital discharge, says study
May 26, 2018 - Lifetime risks of developing Alzheimer’s dementia vary by age, gender
May 26, 2018 - Researchers find novel ways to improve participation in clinical research
May 26, 2018 - Researchers develop methods for measuring free-base nicotine levels in e-cigarettes
May 26, 2018 - AHA: Preterm Birth Could Warn of Mom’s Future Heart Risks
May 26, 2018 - Some calories more harmful than others
May 26, 2018 - Study links cell size with commitment to division
May 26, 2018 - Researchers develop new, rapid blood test to detect liver damage
May 26, 2018 - Researchers discover cascade of immune processes linked to poor outcomes in aggressive breast cancer
May 26, 2018 - New research will use mathematics to solve mysteries in cell biology
May 26, 2018 - Proposed National Resilience Strategy to reverse catastrophic increases in ‘deaths of despair’
May 26, 2018 - Mice remain slim on burger diet
May 26, 2018 - BMC receives $13.5 million award to test methods for delivering childhood anxiety treatment
May 26, 2018 - ‘Right to Try Act’ will not benefit terminally-ill patients
May 26, 2018 - Study reveals novel statistical algorithm to identify potential disease genes
May 26, 2018 - Two genes play vital roles in malignant brain cancer
May 26, 2018 - Study explores link between groundwater lithium and diagnoses of bipolar disorder, dementia
May 26, 2018 - Researchers reveal stimulatory effects of myelin on young neural cells
May 26, 2018 - Small part of cellular protein that helps form long-term memories also drives neurodegeneration
May 26, 2018 - Four-legged friends can have heart issues, too
May 26, 2018 - Scientists create small, self-contained spaces inside mammalian cells
May 26, 2018 - Better Social Support Network Protects Black Men Against HIV
May 26, 2018 - National Heart, Lung, and Blood Institute (NHLBI)
May 26, 2018 - Burnout, depression can affect ophthalmology residents, study finds
May 26, 2018 - Latinos and African Americans more likely to experience serious depression than Whites
May 26, 2018 - Data from past epidemic could help improve response to future Ebola outbreaks
May 26, 2018 - Researchers provide insight into how the memory molecule limits brain plasticity
May 26, 2018 - OSU biologist describes ‘restoration ecology’ approach toward patient health
May 26, 2018 - New approach to study brown fat could aid in finding treatments for obesity
May 26, 2018 - UCI Center on Stress & Health receives NIH funding to develop digital health interventions
May 26, 2018 - Could More Fish in the Diet Boost Sex Lives and Fertility?
May 26, 2018 - NTU Singapore and SERI invent new scope to diagnose glaucoma
May 26, 2018 - Cancer cells co-opt pain-sensing ‘neural channel’ to increase tolerance against oxidative stress
May 26, 2018 - Study uncovers why pesticide exposure increases Parkinson’s disease risk in some people
May 26, 2018 - Study finds link between lead exposure and fertility rates
May 26, 2018 - Causes and treatment of acute heart failure vary by region, registry shows
May 26, 2018 - Delivery of standardized diabetes care could help achieve equitable health outcomes for all patients
May 26, 2018 - FDA authorizes marketing of OsteoDetect software for detecting wrist fractures
May 26, 2018 - HSE experts suggest new way of looking at infantilism
May 26, 2018 - Children and adolescents growing up in extreme societal conditions more likely to resort to violence
May 26, 2018 - New study puts forth most comprehensive tree of life for malaria parasites
May 26, 2018 - UVA researchers establish new guidelines for explorers of the submicroscopic world inside us
May 26, 2018 - Princeton Instruments and C-SOPS announce collaboration on innovative pharmaceutical technology
May 26, 2018 - New research shows why babies need to move in the womb
May 26, 2018 - UK steps forward to tackle global antimicrobial resistance
May 26, 2018 - CRISPR-Cas9-based strategy allows researchers to precisely alter hundreds of different genes
May 26, 2018 - Novoheart announces next generation of ‘Human heart-in-a-jar’ technology for advanced drug discovery
May 26, 2018 - UT Southwestern-led researchers find new way to determine prognosis of invasive kidney cancer
May 26, 2018 - Researchers develop film to prevent bacteria from growing on dental retainers and aligners
May 26, 2018 - Mobile health intervention for people with serious mental illness as effective as clinic-based treatment
First Successful Gene Therapy for Hemophilia A

First Successful Gene Therapy for Hemophilia A

image_pdfDownload PDFimage_print

Action Points

  • This landmark study demonstrated the feasibility of gene transfer to normalize factor VIII levels in adults with hemophilia A.
  • Modest transaminase elevation was common, but self-limited.

ATLANTA — A single infusion of a gene therapy for hemophilia A led to normalization of factor VIII levels that persisted for a year, British investigators reported here.

Six of seven patients treated with the highest dose of the engineered therapy had factor VIII levels >50 IU/dL, and the seventh patient had therapeutic levels of factor VIII at 1 year. The high-dose cohort averaged 16 bleeding episodes a year before treatment and one episode afterward.

The most frequent adverse event was elevated serum alanine aminotransferase (ALT), reported K. John Pasi, MB ChB, PhD, of the Royal London Hospital, at the American Society of Hematology (ASH) meeting. The results were published simultaneously in the New England Journal of Medicine.

“Increases in factor VIII activity levels were dose dependent, with all seven participants in the high-dose cohort sustaining therapeutic levels at 1 year after gene transfer,” Pasi’s group noted in the published article. “In conjunction, the frequency of participant-treated bleeding episodes decreased markedly, with resultant cessation of factor VIII use. The absence of spontaneous bleeding in patients with severe hemophilia A factor VIII replacement therapy, regardless of the product half-life.”

The study is the first successful demonstration of gene therapy for hemophilia, as three previous trials with different genetically engineered products either failed to show a benefit, they added.

Combined with reported success for gene therapy for the less common hemophilia B, the results suggest that a cure for hemophilia may soon be within reach, according to the author of an accompanying editorial.

“These landmark studies … are leading the way to a cure for hemophilia,” wrote H. Marijke van den Berg, MD, PhD, of PedNet Hemophilia Research Foundation in Baarn, the Netherlands. “Prophylaxis with coagulation products could be discontinued in each study, and bleeding rates were reduced to zero, which is to be expected when factor VIII and factor IX levels are sustained at levels exceeding 5 IU per deciliter.”

If the initial results hold up in additional clinical evaluations, “children born with this devastating disease could benefit from a life without bleeding and other sequelae of the disease,” van den Berg added.

During an advance ASH media preview, Robert Brodsky, MD, of Johns Hopkins in Baltimore, included the gene therapy trial in a small group of abstracts that he characterized as “home run-type” studies. Like van den Berg, he said the impressive 52-week results suggest the engineered therapy offers a potential cure for hemophilia A.

The small clinical trial evaluated the safety and efficacy of a codon-optimized adeno-associated virus serotype 5 (AAV5) vector encoding a B-domain-deleted human factor VIII (AAV5). Until the successful results presented by Pasi’s group, the large size of the factor VIII coding region had posed a seemingly insurmountable obstacle improved outcomes in hemophilia A with gene therapy.

Preclinical evaluations of AAV5 (valoctocogene roxaparvovec) showed dose-dependent increases in factor VIII expression in mouse and nonhuman primate models of hemophilia A, providing a rationale for clinical evaluation. Investigators evaluated three doses of the gene therapy in a total of nine men with severe hemophilia A. Low and intermediate doses of the gene therapy (administered to one patient each) failed to achieve and maintain therapeutic levels of factor VIII.

Safety was the primary objective of the trial, and clinical efficacy was a secondary objective. The seven participants in the high-dose cohort and the patient who received the lowest dose of the gene therapy had increased ALT, which was asymptomatic and resolved without intervention or sequelae.

All seven patients in the high-dose cohort achieved therapeutic levels of factor VIII by week 16, the prespecified time point for efficacy assessment. The 5 IU/dL definition for therapeutic level is the cutoff between moderate and mild hemophilia.

“After week 20, the factor VIII activity level was consistently more than 50 IU per deciliter in six of seven participants, and in the remaining participant, the level typically ranged from 12 to 32 IU per deciliter,” the authors noted.

At week 52, the median factor VIII activity level for the high-dose cohort was 77 IU/dL.

In addition to the decline in bleeding episodes that accompanied the increase in factor VIII levels, the requirement for factor VIII also declined dramatically. The median annualized use of factor VIII decreased from 138 infusions per year pre-study to two infusions per year following gene therapy.

Analysis of biologic fluids and stool samples showed that residual vector DNA decreased over the course of the study period.

The authors pointed out that they did not assess the possibility of vector integration, and that the study protocol was not “designed to measure whether AAV5 infection was present in family members or close contacts.”

Pasi disclosed relevant relationships with Bayer HealthCare, Biotest, Novo Nordisk, Pfizer, Roche, SOBI, Octapharma, Shire, Alnylam, Biomarin, and Biogen Idec.

Van den Berg disclosed relevant relationshps with Bayer, CSL, NovoNordisk, Pfizer, Grifols, Sobi, and Bioverativ.

  • Reviewed by
    F. Perry Wilson, MD, MSCE Assistant Professor, Section of Nephrology, Yale School of Medicine and Dorothy Caputo, MA, BSN, RN, Nurse Planner

2017-12-09T09:04:50-0500

Tagged with:

About author

Related Articles